Gambiense human African trypanosomiasis: the bumpy road to elimination

Purpose of review Gambiense human African trypanosomiasis (gHAT), a disease that has killed hundreds of thousands as recently as the 1990s, could be on the verge of elimination or even eradication. This review describes recent developments that give us reasons for optimism as well as some caveats. Recent findings New developments in diagnostic and vector control tools, and especially in treatment, make it possible to strive for elimination of transmission of gHAT by 2030, perhaps even eradication. Summary Gambiense human African trypanosomiasis is a deadly infectious disease affecting West and Central Africa, South Sudan and Uganda, and transmitted between humans by tsetse flies. The disease has caused several major epidemics, the latest one in the 1990s. Thanks to recent innovations such as rapid diagnostic tests for population screening, a single-dose oral treatment and a highly efficient vector control strategy, interruption of transmission of the causative parasite is now within reach. If indeed gHAT has an exclusively human reservoir, this could even result in eradication of the disease. Even if there were an animal reservoir, on the basis of epidemiological data, it plays a limited role. Maintaining adequate postelimination surveillance in known historic foci, using the newly developed tools, should be sufficient to prevent any future resurgence.

[1]  G. Cecchi,et al.  The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020 , 2022, PLoS neglected tropical diseases.

[2]  H. Bergman,et al.  Chemotherapy for second‐stage human African trypanosomiasis: drugs in use , 2021, The Cochrane database of systematic reviews.

[3]  A. Tarral,et al.  Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection , 2021, PLoS neglected tropical diseases.

[4]  A. Tarral,et al.  Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study , 2021, The Lancet. Global health.

[5]  J. Longbottom,et al.  Estimating the impact of Tiny Targets in reducing the incidence of Gambian sleeping sickness in the North-west Uganda focus , 2021, Parasites & vectors.

[6]  M. Malecela,et al.  A road map for neglected tropical diseases 2021–2030 , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  J. Longbottom,et al.  Trypa-NO! contributes to the elimination of gambiense human African trypanosomiasis by combining tsetse control with “screen, diagnose and treat” using innovative tools and strategies , 2020, PLoS neglected tropical diseases.

[8]  L. E. Eyssen,et al.  Trypanosoma brucei gambiense-iELISA: A Promising New Test for the Post-Elimination Monitoring of Human African Trypanosomiasis , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Stanton,et al.  Impact of tiny targets on Glossina fuscipes quanzensis, the primary vector of human African trypanosomiasis in the Democratic Republic of the Congo , 2020, bioRxiv.

[10]  M. Barrett,et al.  New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story , 2020, Tropical medicine and infectious disease.

[11]  H. Hänel,et al.  Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole , 2020, Tropical medicine and infectious disease.

[12]  E. Akl,et al.  New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. , 2019, The Lancet. Infectious diseases.

[13]  E. N'Goran,et al.  Population genetics of Glossina palpalis palpalis in sleeping sickness foci of Côte d’Ivoire before and after vector control , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[14]  E. Bottieau,et al.  Human African Trypanosomiasis: Progress and Stagnation. , 2019, Infectious disease clinics of North America.

[15]  M. Boelaert,et al.  Innovative digital technologies for quality assurance of diagnosis of human African trypanosomiasis , 2018, PLoS neglected tropical diseases.

[16]  Crispin Lumbala,et al.  Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens , 2018, PLoS neglected tropical diseases.

[17]  N. Chitnis,et al.  Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? , 2018, Trends in parasitology.

[18]  A. Tarral,et al.  Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial , 2018, The Lancet.

[19]  Giuliano Cecchi,et al.  Human African trypanosomiasis , 2017, The Lancet.

[20]  P. Lutumba,et al.  Performance of the SD BIOLINE® HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo , 2017, PloS one.

[21]  S. Brand,et al.  Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad) , 2017, PLoS neglected tropical diseases.

[22]  A. MacLeod,et al.  The skin is a significant but overlooked anatomical reservoir for vector-borne African trypanosomes , 2016, eLife.

[23]  M. Camara,et al.  Reducing Human-Tsetse Contact Significantly Enhances the Efficacy of Sleeping Sickness Active Screening Campaigns: A Promising Result in the Context of Elimination , 2015, PLoS neglected tropical diseases.

[24]  S. Torr,et al.  Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy , 2015, PLoS neglected tropical diseases.

[25]  F. Checchi,et al.  Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis , 2015, BMC Research Notes.

[26]  S. Torr,et al.  Costs Of Using “Tiny Targets” to Control Glossina fuscipes fuscipes, a Vector of Gambiense Sleeping Sickness in Arua District of Uganda , 2015, PLoS neglected tropical diseases.

[27]  M. Camara,et al.  Accuracy of Individual Rapid Tests for Serodiagnosis of Gambiense Sleeping Sickness in West Africa , 2015, PLoS neglected tropical diseases.

[28]  M. Boelaert,et al.  Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo , 2015, Tropical medicine & international health : TM & IH.

[29]  Marleen Boelaert,et al.  Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. , 2014, The Lancet. Global health.

[30]  G. Cecchi,et al.  Mapping the capacities of fixed health facilities to cover people at risk of gambiense human African trypanosomiasis , 2014, International Journal of Health Geographics.

[31]  T. Robinson,et al.  Estimating the costs of tsetse control options: an example for Uganda. , 2013, Preventive veterinary medicine.

[32]  Michel Quere,et al.  Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Boelaert,et al.  Should I Get Screened for Sleeping Sickness? A Qualitative Study in Kasai Province, Democratic Republic of Congo , 2012, PLoS neglected tropical diseases.

[34]  S. Torr,et al.  Towards an Optimal Design of Target for Tsetse Control: Comparisons of Novel Targets for the Control of Palpalis Group Tsetse in West Africa , 2011, PLoS neglected tropical diseases.

[35]  S. Torr,et al.  Improving the Cost-Effectiveness of Visual Devices for the Control of Riverine Tsetse Flies, the Major Vectors of Human African Trypanosomiasis , 2011, PLoS neglected tropical diseases.

[36]  V. Jamonneau,et al.  Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for Sleeping Sickness Diagnosis and Staging , 2009, PLoS neglected tropical diseases.

[37]  Salah Ghabri,et al.  Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.

[38]  S. Torr,et al.  Improving the Cost-Effectiveness of Artificial Visual Baits for Controlling the Tsetse Fly Glossina fuscipes fuscipes , 2009, PLoS neglected tropical diseases.

[39]  F. Chappuis.  Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  M. Barrett.  The rise and fall of sleeping sickness , 2006, The Lancet.

[41]  F. Chappuis,et al.  Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  M. Boelaert,et al.  The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo , 2004, Tropical medicine & international health : TM & IH.

[43]  C. M. Bilenge,et al.  Sleeping sickness resurgence in the DRC: the past decade , 2001, Tropical medicine & international health : TM & IH.

[44]  J. Atouguia,et al.  The importance of 2,3-dimercaptopropinol (British anti-lewisite, BAL) in the trypanocidal activity of topical melarsoprol. , 1996, Acta tropica.

[45]  Control and surveillance of human African trypanosomiasis. , 2013, World Health Organization technical report series.

[46]  F. Chappuis,et al.  Sleeping sickness. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[47]  L. Tshilolo,et al.  [Medicine and health in the Democratic Republic of Congo: from Independence to the Third Republic]. , 2007, Medecine tropicale : revue du Corps de sante colonial.

[48]  C. Burri,et al.  Clinical aspects of 2541 patients with second stage human African trypanosomiasis. , 2006, Acta tropica.

[49]  H. Méda,et al.  The epidemiology and control of human African trypanosomiasis. , 2001, Advances in parasitology.

[50]  F. Milord,et al.  The treatment of human African trypanosomiasis. , 1994, Advances in parasitology.

[51]  N. Van Meirvenne,et al.  A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. , 1978, Annales de la Societe belge de medecine tropicale.